戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HRID 2091456作成日:2026年10月25日

Dihydropyrimidine → Tegafur

https://huagongshe.com/reaction/2091456

反応式

関与物質

役割名称HCID仕込み量
反応物DihydropyrimidineHCID 1056—
反応物5-FluorouracilHCID 3385—
反応物NADPHHCID 5884—
反応物alpha-Fluoro-beta-alanineHCID 13351—
反応物DoxifluridineHCID 18343—
反応物5,6-Dihydro-5-fluorouracilHCID 121997—
反応物Ammonium AcetateHCID 517165—
溶媒EthanolHCID 702—
生成物TegafurHCID 5386—
生成物CapecitabineHCID 60953—

反応手順

100 μM NADPH and 25 μl of cell supernatant (reaction volume; 50 μl) were incubated at 37° C. for 30 min. After the reaction, 5 μl of the reaction solution was subjected to thin layer chromatography (Silica gel 60F254; Merck, Germany) and developed with a mixed solution of ethanol and 1 M ammonium acetate (5:1, v/v). Dihydropyrimidine dehydrogenase activity was determined by measuring the sum of dihydrofluorouracil and 2-fluoro-β-alanine dissociated from [6-14C] 5-FU with a liquid scintillation counter. Drugs used: UFT, TS-1 and capecitabine were synthesized by Taiho Pharmaceutical Co., Ltd. 5′-DFUR was purchased from Roche Japan. [6-14C]-5-FU (1.85 GBq/mmol) was purchased from Moravek Biochemicals, Inc. (Brea, Calif., USA).

情報源と証拠

DOI10.6084/m9.figshare.5104873.v1
特許番号US08440398B2
出典データセットuspto-grants-2013_05
ORD IDord-08bf9dab220c4455a76fa5eff9def14f
出典メモuspto-grants-2013_05